aPLs, which can appear in SLE and APS patients, are a heterogeneous group of autoantibodies reacting against phospholipids, phospholipid-protein complexes, and phospholipid-binding proteins, including lupus anticoagulant (LA), anticardiolipin (aCL) and anti-beta2 glycoprotein I (anti-β2GP1) antibodies [15]. The gene discussed is ACLY; the disease is systemic lupus erythematosus.